Current Problems in Cardiology
Volume 31, Issue 7 , Pages 445-486 , July 2006

Pathophysiology, Diagnosis, and Management of Dyslipidemia

References 

  1. Topol E . Intensive statin therapy—a sea change in cardiovascular prevention . New Engl J Med . 2004;350:15
  2. Wright RS , Kottke TE , Gau GT . Lipid-lowering Agents . In:  Murphy J editors. Mayo Clinic Cardiology Review . 2nd Ed.. Philadelphia, PA: Lippincott Williams & Wilkins; 2000;p. 1301–1318
  3. Roberts WC . The underused miracle drugs (the statin drugs are to atherosclerosis what penicillin was to infection disease) . Am J Cardiol . 1996;78:377–378
  4. Grundy SM , Cleeman JL , Bairey Mertz N , et al.   Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines . Circulation . 2004;110:227–239
  5. Kromhout D . On the waves of the Seven Countries Study (a public health perspective on cholesterol) . Eur Heart J . 1999;20:796–802
  6. Vaughn CJ , Murphy MB , Buckley BM . Statins do more than just lower cholesterol . Lancet . 1996;348(9034):1079–1082
  7. Libby P . Molecular bases of the acute coronary syndromes . Circulation . 1995;91(11):2844–2850
  8. Stary HC , Chandler AB , Dinsmore RE , et al.   A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis . Circulation . 1995;92(5):1355–1374
  9. Fuster V . Mechanisms leading to myocardial infarction (insights from studies of vascular biology) . Circulation . 1994;90:2126–2146
  10. Glass CK , Witztum JL . Atherosclerosis (the road ahead) . Cell . 2001;14:503–516
  11. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (ATP-III) . JAMA . 2001;285:2486–2497
  12. Kromhout D . On the waves of the Seven Countries Study—a public health perspective on cholesterol . Eur Heart J . 1999;20:796–802
  13. Vaughn CJ , Gotto AM . Update on statins 2003 . Circulation . 2004;110:886–892
  14. Shepherd J , Cobbe SM , Ford I , et al.  West of Scotland Coronary Prevention Study Group   Prevention of coronary artery disease with pravastatin in men with hypercholesterolemia . N Engl J Med . 1995;333:1301–1307
  15. Randomized trial of cholesterol lowering in 4444 patients with coronary artery disease (the Scandinavian Simvastatin Survival Study (4S)) . Lancet . 1994;344:1383–1389
  16. Sacks FM , Pfeffer MA , Moye LA , et al.  Cholesterol and recurrent trial investigators   The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels . N Engl J Med . 1996;335:1000–1009
  17. Long-term intervention with pravastatin in ischemic disease (LIPID) study group . Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels . N Engl J Med . 1998;339:1349–1357
  18. Downs JR , Clearfield M , Weis S , et al.   Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels (results of AFCAPS/TexCAPS) . JAMA . 1998;279:1615–1622
  19. Pedersen TR, Kjekshus J, Pyorala K, et al. Presented at American Heart Association Annual Meeting. Circulation 1995;92(8):1-672, abstract no. 3225.
  20. Haffner SM , Lehto S , Ronnemaa T , et al.   Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction . N Engl J Med . 1998;339:229–234
  21. Sniderman AD , Furberg CD , Keech A , et al.   Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment . Lancet . 2003;361:777–780
  22. Otvos JD , Jeyarajah EJ , Cromwell WC . Measurement issues related to lipoprotein heterogeneity . Am J Cardiol . 2002;90(8A):22i–29i
  23. Omar MA , Wilson JP , Cox TS . Rhabdomyolysis and HMG-CoA reductase inhibitors . Ann Pharmacother . 2001;35:1096–1107
  24. Prueksaritanont T . Glucuronidation of statins in animals and humans (a novel mechanism of statin lactonization) . Drug Metab Dispos . 2002;30:505–512
  25. Prueksaritanont T , Tang C , Qiu Y , et al.   Effects of fibrates on metabolism of statins in human hepatocytes . Drug Metab Dispos . 2002;30:1280–1287
  26. Pastermak RC , Smith SC , Bairey-Merz CN , et al.   ACC/AHA/NHLBI clinical advisory on the use and safety of statins . Circulation . 2002;106:1024–1028
  27. Thompson PD , Clarkson P , Karas RH . Statin-associated myopathy . JAMA . 2003;289:1682–1690
  28. Rosenson RS . Current overview of statin-induced myopathy . Am J Med . 2004;116:408–416
  29. Laaksonen R , Jokelainen K , Sahi T , et al.   Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-term simvastatin treatment in humans . Clin Pharmacol Ther . 1995;57:62–66
  30. Phillips PS , Haas RH , Bannykh S , et al.   Statin-associated myopathy with normal creatine kinase levels . Ann Intern Med . 2002;137:581–585
  31. Raskind JY , El-Chaar GM . The role of carnitine supplementation during valproic and therapy . Ann Pharmacother . 2003;34:630–638
  32. Ogasahara S , Engel AG , Frens D , et al.   Muscle coenzyme Q deficiency in familial mitochondrial encephalomyopathy . Proc Natl Acad Sci USA . 1989;86:2379–2382
  33. Coleman ML , Olson MF , Rho GT . Pase signaling pathways in the morphological changes associated with apoptosis . Cell Death Differ . 2002;9:493–504
  34. Olson MF , Ashworth A , Hall A . An essential role for Rho, Rad, and Cdc42 GTPases in cell cycle progression through G1 . Science . 1995;269:1270–1272
  35. Pasternak RC , Smith SC , Bairey-Merz CN , et al.   ACC/AHA/NHLBI Clinical Advisory on the use of safety of statins . Circulation . 2002;1024–1028
  36. Moosmann B , Behl C . Selenoprotein synthesis and side-effects of statins . Lancet . 2004;363:892–894
  37. Pfeffer MA , Keech A , Sacks FM , et al.   Safety and tolerability of pravastatin in long-term clinical trials (prospective pravastatin pooling (PPP) project) . Circulation . 2002;105:2341–2346
  38. Thompson PD , Clarkson P , Karas RH . Stating-induced myopathy . JAMA . 2003;289:1682–1690
  39. Staffa JA , Chang J , Green L . Cerivastatin and reports of fatal rhabdomyolysis . N Engl J Med . 2002;346:539–540
  40. Data file—personal communication and package insert data. AstraZeneca LP, Alderley Park, Macclesfield, Cheshire, UK; 1998-2003.
  41. Jones PH , Davidson MH , Stein EA , et al.  STELLAR Study Group   Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial) . Am J Cardiol . 2003;92(2):152–160
  42. Hunninghake DB , Stein EA , Bays HE , et al.   Rosuvastatin improves the atherogenic and atheroprotective lipid profiles in patients with hypertriglyceridemia . Coron Artery Dis . 2004;15:115–123
  43. Schneck DW , Knopp RH , Ballantyne CM , et al.   Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease . Am J Cardiol . 2003;91(1):33–41
  44. Stein EA , Strutt K , Southworth H , et al.   Comparison of rosuvastatin versus atorvastatin in patients with heterozygous familial hypercholesterolemia . Am J Cardiol . 2003;92:1287–1293
  45. Berry DA , Berry SM , McKellar J , et al.   Comparison of the dose-response relationships of two lipid-lowering agents (a Bayesian meta-analysis) . Am Heart J . 2003;145(6):1036–1045
  46. The Heart Protection Study Investigators . MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals (a randomized placebo-controlled trial) . Lancet . 2002;360:7–22
  47. Cannon CP , Braunwald E , McCabe CH , et al.   Intensive versus moderate lipid-lowering with statins after acute coronary syndromes . N Engl J Med . 2004;350:1495–1504
  48. Nissen SE , Tuzcu EM , Schoenhagen P , et al.   Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis (a randomized controlled trial) . JAMA . 2004;291:1071–1080
  49. Hsu I , Spinler SA , Johnson NE . Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia . Ann Pharmacother . 1995;29:743–759
  50. Bradford RH , Shear CL , Chremos AN , et al.   Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia . Arch Intern Med . 1991;151:43–49
  51. Pedersen TR , Tobert JA . Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease (a reappraisal) . Drug Saf . 1996;14:11–24
  52. Angelo P . Nonalcoholic fatty liver disease . N Engl J Med . 2002;346:1221–1231
  53. Prueksaritanont T , Tang C , Qiu Y , et al.   Effects of fibrates on metabolism of statins in human hepatocytes . Am Soc Pharm Exp Ther . 2002;30(11):1280–1287
  54. Knopp RH , Gitter H , Truitt T , et al.   Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia . Eur Heart J . 2003;24:729–741
  55. Sudhop T , Lutjohann D , Kodal A , et al.   Inhibition of intestinal cholesterol absorption by ezetimibe in humans . Circulation . 2002;106:1943–1948
  56. Gagne C , Bays HE , Weiss SR , et al.   Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with hypercholesterolemia . Am J Cardiol . 2002;90:1084–1091
  57. Dujovne CA , Ettinger MP , McNeer JF . Efficacy and safety of a potent new selective cholesterol absorption inhibitor, in ezetimibe, in patients with primary hypocholesterolemia . Am J Cardiol . 2002;90:1092–1097
  58. Davidson MT , McGarry T , Bettis R , et al.   Ezetimibe co-administered with simvastatin in patients with primary hypercholesterolemia . J Am Coll Cardiol . 2002;40:2125–2134
  59. Roberts WC . Two more drugs for dyslipidemia . Am J Card . 2004;93:809–811
  60. Sager PT , Melani L , Lipka L , et al.   Effect of coadministration of ezetimibe and simvastatin on high-sensitivity c-reactive protein . Am J Cardiol . 2003;92:1414–1418
  61. Zema MJ, Chan E. Ezetimibe and colesevelam are additive in the management of hypercholesterolemia. Presented at the American College of Chest Physicians meeting 2004, abstract.
  62. Nguyen TT , Dale LC , vonBergmann K , et al.   Cholesterol-lowering effect of stanol ester in a US population of mildly hypercholesterolemic men and women (a randomized controlled trial) . Mayo Clin Proc . 1999;74(12):1198–1206
  63. Brewer HB . Increasing HDL cholesterol levels . N Engl J Med . 2004;350:15; 1491-4
  64. Brousseau ME , Schaefer EJ , Wolfe ML , et al.   N Engl J Med . 2004;350(15):1505–1515
  65. Nissen SE , Tsunoda T , Tuzcu EM , et al.   Effect of recombinant Apo A1 milano on coronary atherosclerosis in patients with acute coronary syndromes (a randomized controlled trial) . JAMA . 2003;290:2292–2300
  66. Li D , Weng S , Yang B , et al.   Inhibition of arterial thrombus formation by Apo A1 milano . Arterioscler Thromb Vasc Biol . 1999;19:378–383
  67. Bybee KA , Wright RS , Williams BA , et al.   Effect of concomitant or very early statin administration on in-hospital mortality and reinfarction in patients with acute myocardial infarction . Am J Cardiol . 2001;87:771–774
  68. Schiefe R , Gitt AK , Heer T , et al.   Early statin use in acute myocardial infarction is associated with a reduced hospital mortality (results of the Mitra-2) . Circulation . 2000;102:II-435
  69. Stenestrand U , Wallentin L . Early statin treatment following acute myocardial infarction and 1-year survival . JAMA . 2001;285:430–436
  70. Bybee KA , Wright RS , Powell BD , et al.   Differential benefit from treatment with a statin agent at hospital discharge in non-ST elevation MI compared to ST elevation MI . Circulation . 2000;102(suppl 2):II-614; [Abstract 2977]
  71. Aronow HD , Topol EJ , Roe MT , et al.   Effect of lipid lowering therapy on early mortality after acute coronary syndromes (an observational study) . Lancet . 2001;357:1063–1068
  72. Giugliano RP , Antman EM , Thompson SL , et al.   Lipid lowering drug therapy initiated during hospitalization for acute MI is associated with lower post-discharge 1-year mortality . J Am Coll Cardiol . 2001;37(suppl A):316A; [Abstract 1053-91]
  73. Cannon CP , McCabe CH , Bentley J , et al.   Early statin therapy is associated with markedly lower mortality in patients with acute coronary syndromes (observations from OPUS-TIMI 16) . J Am Coll Cardiol . 2001;37(suppl A):334A; [Abstract 831-2]
  74. McGuire DK , Kristinsson A , Bhapkar MV , et al.   Early statin use after acute coronary syndromes (ACS) and outcomes at 90 days . Circulation . 2001;104:II-343
  75. Kayikcioglu M , Can L , Kultursay H , et al.   Early use of pravastatin in patients with acute myocardial infarction undergoing coronary angioplasty . Acta Cardiol . 2002;57:295–302
  76. Van Boven AJ, Liem A. Effects of fluvastatin administration immediately after an acute myocardial infarction on myocardial ischemia (FLORIDA). Presented at: American Heart Association Scientific Session 2000; November 12-15, 2000; New Orleans, LA. Available at: http://www.acc.org/education/online/trials/aha00/florida.htm
  77. Schwartz GG , Olsson AG , Ezekowitz MD , et al.   Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes (the MIRACL study) . JAMA . 2001;285(13):1711–1718
  78. Arntz HR , Agrawal R , Wunderlich W , et al.   Beneficial effects of pravastatin (+/−colestyramine/niacin) initiated immediately after a coronary event (the randomized Lipid-Coronary Artery Disease [L-CAD] Study) . Am J Cardiol . 2000;86:1293–1298
  79. Wright RS , Murphy JG , Bybee KA , et al.   Statin lipid-lowering therapy for acute myocardial infarction and unstable angina (efficacy and mechanism of benefit) . Mayo Clin Proc . 2002;77:1085–1092
  80. Blazing MA , de Lemos JA , Dyke CK , et al.   The A-to-Z Trial (methods and rationale for a single trial investigating combined with use of a low-molecular-weight heparin with the glycoprotein IIb/III inhibitor tirofiban and defining the efficacy of early aggressive simvastatin therapy) . Am Heart J . 2001;142:211–217
  81. Ross AM , Coyne KS , Reiner JS , et al.  PACT investigators   A randomized trial comparing primary angioplasty with a strategy of short-acting thrombolysis and immediate planned rescue angioplasty in acute myocardial infarction (the PACT trial) . J Am Coll Cardiol . 1999;34(7):1963–1965
  82. de Lemos JA , Blazing MA , Wiviott SD , et al.   Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes . JAMA . 2004;292(11):1307–1316
  83. Fonarow GC , French WJ , Parsons LS , et al.   Use of lipid-lowering medications at discharge in patients with acute myocardial infarction (data from the National Registry of Myocardial Infarction 3) . Circulation . 2001;103(1):38–44
  84. Bybee KA , Powell BD , Williams BA , et al.   Superior short-term cholesterol control and achievement of the adult treatment panel III low-density lipoprotein goals with initiation of statin therapy by the time of hospital discharge following acute myocardial infarction . Am J Cardiol . 2004;93:776–779
  85. Rosenson RS , Tangey CC . Antiatherothrombotic properties of statins. Implications for cardiovascular event reduction . JAMA . 1998;279:1643–1650
  86. Vaughan CJ , Murphy MB , Buckley BM . Statins do more than lower cholesterol . Lancet . 1996;348:1079–1082
  87. Herrmann J , Lerman A , Baumgarat D , et al.   Preprocedural statin medication reduces the extent of periprocedural non-Q wave myocardial infarction . Circulation . 2002;106:2180–2183
  88. Bybee KA , Kopecky SL , Williams BA , et al.   Reduced creatine kinase release with statin use at the time of myocardial infarction . Intl J Card . 2004;96(3):461–466
  89. Laufs U , La Fata V , Plutzky J , et al.   Upregulation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors . Circulation . 1998;97:1129–1135
  90. Sever PS , Dahlof B , Poulter NR , et al.  ASCOT Investigators   Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA) (a multicentre randomized controlled trial) . Lancet . 2003;361:1149–1158
  91. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group . Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin versus usual care. The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT-LLT) . JAMA . 2002;288:2998–3007
  92. Kim C , Gau GT , Allison TG . Relation of high lipoprotein(a) to other traditional atherosclerotic risk factors in patients with coronary heart disease . Am J Cardiol . 2003;91:1360–1363
  93. Marcovina SM , Koschinsky ML , Albers JJ , et al.   Report of the National Heart, Lung, and Blood Institute Workshop on lipoprotein(a) and cardiovascular disease (recent advances and future directions) . Clin Chem . 2003;49:1785–1896
  94. Deb A , Caplice N . Lipoprotein A. New insights into mechanisms of atherogenesis and thrombosis . Clin Cardiol . 2004;27:258–264
  95. Bostrom LA , Cupples JL , Jenner L , et al.   Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger—a prospective study . JAMA . 1996;276:544–548
  96. van Wissen S , Smilde TJ , Trip MD , et al.   Long term statin treatment reduces lipoprotein(a) concentrations in heterozygous familial hypercholesterolaemia . Heart . 2003;89:893–896
  97. Maher VM , Brown BG , Marcovina LA , et al.   Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a) . JAMA . 1995;274(22):1771–1774
  98. Shlipak MG , Simon JA , Vittinghoff E , et al.   Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause . JAMA . 2000;283:1845–1852
  99. Gauthier GM , Keevil JG , McBride PE . The association of homocysteine and coronary artery disease . Clin Cardiol . 2003;26:563–568
  100. Wald DS , Law M , Morris J . Serum homocysteine and the severity of coronary artery disease . Thromb Res . 2003;111:55–57
  101. Matetzky S , Freimark D , Ben-Ami S , et al.   Association of elevated homocysteine levels with a higher risk of recurrent coronary events and mortality in patients with acute myocardial infarction . Arch Intern Med . 2003;163:1933–1937
  102. Weisberg IS , Park E , Ballman KV , et al.   Investigations of a common genetic variant in betaine-homocysteine methyltransferase (BHMT) in coronary artery disease . Atherosclerosis . 2003;167:205–214
  103. Ridker PM , Rifai N , Pfeffer MA , et al.   Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels . Circulation . 1998;98:839–844
  104. Ridker PM , Rifai N , Pfeffer MA , et al.  The Cholesterol and Recurrent Events (CARE) Investigators   Long-term effects of pravastatin on plasma concentration of C-reactive protein . Circulation . 1999;100(3):230–235
  105. Ridker PM , Rifai N , Clearfield M , et al.   Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events . N Engl J Med . 2001;344:1959–1965
  106. Ridker PM , Cannon CP , Morrow D , et al.   C-reactive protein levels and outcomes after statin therapy . N Engl J Med . 2005;352:20–28
  107. Rubins HB , Robins SJ , Collins J , et al.   Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol . N Engl J Med . 1999;341:410–418

 Disclosures: Gerald T. Gau, MD, Principle investigator in the COURAGE Trial and a member of the Executive Committee, was supported by the Department of Veterans Affairs Cooperative Studies Program, in collaboration with the Canadian government CIHR. R. Scott Wright, MD, received research support from Bayer, Bristol-Myers Squibb, Merck, and Johnson & Johnson and worked as a consultant for Pfizer and Merck-Schering Plough.

PII: S0146-2806(06)00036-3

doi: 10.1016/j.cpcardiol.2006.03.001

Current Problems in Cardiology
Volume 31, Issue 7 , Pages 445-486 , July 2006

Article Tools

* Image Usage & Resolution